IceCure Medical (NASDAQ:ICCM) Releases Earnings Results, Misses Expectations By $0.01 EPS

IceCure Medical (NASDAQ:ICCM) announced its quarterly earnings results on Thursday. The company reported ($0.08) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.01), Zacks reports. IceCure Medical had a negative net margin of 376.85% and a negative return on equity of 124.44%. The firm had revenue of $1.07 million during the quarter, compared to analyst estimates of $1.07 million.

IceCure Medical Stock Performance

ICCM stock opened at $1.11 on Friday. IceCure Medical has a 1-year low of $0.48 and a 1-year high of $1.66. The company has a current ratio of 2.67, a quick ratio of 2.27 and a debt-to-equity ratio of 0.02. The firm has a market cap of $61.61 million, a PE ratio of -3.83 and a beta of 0.37. The business’s 50-day moving average price is $1.32 and its two-hundred day moving average price is $0.99.

Analysts Set New Price Targets

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $2.50 target price on shares of IceCure Medical in a research note on Friday.

IceCure Medical Company Profile

IceCure Medical Ltd, a commercial stage medical device company, engages in the research, development, and marketing of cryoablation systems, disposables, and technologies for treating tumors. The company offers ProSense system, a single probe system for the treatment of tumors, as well as associated disposables; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology.